Is Carole Ho’s Royalty Pharma (RPRX) share award an open-market purchase or compensation grant?

The 4,545-share transaction is a compensation-related grant, not an open-market purchase. It is coded as a grant or award acquisition, with a price of $0.00 per share, reflecting equity compensation under Royalty Pharma’s independent director equity incentive plan.

Royalty Pharma director receives 4,545-share equity grant

Ho Carole reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ho Carole reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Carole Ho reported a grant of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was made at a price of $0.00 per share as compensation and is scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award terms. Following this grant, Ho holds 4,545 shares directly and 8,558 shares indirectly through the Rohatgi-Ho Family 2009 Revocable Trust, where she serves as trustee.

Insider Trade Summary

Grant/Award: 4,545 shares

Grant/Award 2 txns

Insider Ho Carole

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	$0.00
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 4,545 shares (Direct); Class A Ordinary Shares — 8,558 shares (Indirect, See footnote)

Footnotes (2)

F1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
F2. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

Key Figures

RSU grant size: 4,545 shares Grant price: $0.00 per share Direct holdings after grant: 4,545 shares +2 more

5 metrics

RSU grant size 4,545 shares Class A Ordinary Shares granted as award acquisition

Grant price $0.00 per share Equity compensation, not open-market purchase

Direct holdings after grant 4,545 shares Total Class A Ordinary Shares held directly by Carole Ho

Indirect holdings 8,558 shares Held by Rohatgi-Ho Family 2009 Revocable Trust

Vesting schedule 100% cliff vesting Earlier of one-year anniversary or next annual shareholder meeting

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, Revocable Trust

3 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

Revocable Trust financial

"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Carole Ho report in Royalty Pharma (RPRX)?

Carole Ho reported receiving 4,545 Class A Ordinary Shares as a restricted stock unit award. The grant was made at $0.00 per share as director compensation and is subject to vesting conditions under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan.

How many Royalty Pharma (RPRX) shares did Carole Ho acquire in this Form 4?

Carole Ho acquired 4,545 Class A Ordinary Shares through a grant coded as an award acquisition. These shares were granted at no cash cost to her and represent equity compensation rather than an open-market purchase of Royalty Pharma stock.

What are the vesting terms of Carole Ho’s restricted stock units in Royalty Pharma (RPRX)?

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of Royalty Pharma’s next annual shareholder meeting. Vesting remains subject to the 2020 Independent Director Equity Incentive Plan and the related award agreement.

How many Royalty Pharma (RPRX) shares does Carole Ho hold after this transaction?

After the reported transactions, Carole Ho holds 4,545 Class A Ordinary Shares directly. She also has indirect ownership of 8,558 shares held by the Rohatgi-Ho Family 2009 Revocable Trust, for which she serves as trustee, according to the Form 4 disclosure.

How are Carole Ho’s indirect Royalty Pharma (RPRX) shares held?

The Form 4 states that 8,558 Class A Ordinary Shares are held by the Rohatgi-Ho Family 2009 Revocable Trust. Carole Ho serves as trustee of this trust, so these shares are reported as indirect ownership, separate from her directly held 4,545 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 04:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho Carole

(Last)

(First)

(Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Shares	06/05/2026		A		4,545⁽¹⁾	A	$0	4,545	D
Class A Ordinary Shares								8,558	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

2. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Carole Ho	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR